Dianthus | Affinity Screening

  • Because you demand fast, non-stop, highly sensitive hit screening.

    Because you demand fast, non-stop, highly sensitive hit screening.

    Read
  • Get fast, non-stop, highly sensitive hit screening with Dianthus.2:55

    Get fast, non-stop, highly sensitive hit screening with Dianthus.

    Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi

    Watch
  • Understanding the nuances of targeted protein degradation59:35

    Understanding the nuances of targeted protein degradation

    Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte

    Watch
  • Have a question about Dianthus?

    Contact Specialist
  • Going small to win big: Fragment-based screening in drug discovery

    Going small to win big: Fragment-based screening in drug discovery

    Read
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read
  • 3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs

    3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs

    A caveat to a successful pharmaceutical industry in which many effective drugs have already been discovered is the notion that the high hanging fruits left unpicked come in the form of challenging...

    Read
  • The NanoTemper Story – Chapter 5: The Dianthus

    The NanoTemper Story – Chapter 5: The Dianthus

    Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....

    Read
  • High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    Read
  • Tackle the high-hanging fruits in challenging drug discovery pipelines17:10

    Tackle the high-hanging fruits in challenging drug discovery pipelines

    There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

    Watch
  • Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space

    Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space

    Read
  • Easily characterize the molecular mechanisms of neurodegenerative diseases

    Easily characterize the molecular mechanisms of neurodegenerative diseases

    Read
  • Fast-track your hit screening assay development with the Buffer Exploration Kit

    Fast-track your hit screening assay development with the Buffer Exploration Kit

    Read
  • Tackle small molecule drug discovery screening challenges with Dianthus17:07

    Tackle small molecule drug discovery screening challenges with Dianthus

    A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are eit

    Watch
  • 3 big takeaways from SLAS on the future of automation and screening

    3 big takeaways from SLAS on the future of automation and screening

    5,200 researchers, representing all of life sciences, gathered in San Diego in late January to discuss the latest in automation and screening solutions. Improvements in automation and screening...

    Read
  • Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments16:04

    Neurodegenerative Diseases: Studying protein aggregation using NanoTemper instruments

    Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Although current treatments may help relieve some of the physical or mental symptoms, there is s

    Watch
  • When aptamers are the better choice over mAbs

    When aptamers are the better choice over mAbs

    Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is needed for a variety of applications including disease diagnosis and therapy....

    Read
  • 6 ingredients for a successful fragment library

    6 ingredients for a successful fragment library

    Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in drug discovery. The principle of FBDD is to start with very small molecular fragments which may...

    Read
  • 4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    Read
  • PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...

    Read
  • 5 things you must do while in Liverpool for ELRIG Drug Discovery

    5 things you must do while in Liverpool for ELRIG Drug Discovery

      Here’s how to make your trip unforgettable.     1. Immerse yourself in Liverpool’s historic heart at the Royal Albert Dock This is the place to be for many iconic Liverpool attractions. Discover...

    Read
  • loading
    Loading more...